Tag: Luminor DCB

Episode 1: Luminor DCB in the femoropopliteal segment: Outstanding safety and...

NOTE: This video is ONLY available to watch in selected countries and geographies Koen Deloose (Dendermonde, Belgium) moderates a three-part Vascular News series about the Luminor...

Episode 2: Experience of Luminor DCB in the below-the-knee segment

NOTE: This video is ONLY available to watch in selected countries and geographies Koen Deloose (Dendermonde, Belgium) moderates a three-part Vascular News series about the Luminor...

Episode 3: Not all DCBs are the same: Luminor TransferTech nanotechnology...

NOTE: This video is ONLY available to watch in selected countries and geographies  Koen Deloose (Dendermonde, Belgium) moderates a three-part Vascular News series about the Luminor...
Luminor

“No signal of increased risk of long-term mortality” with paclitaxel-coated Luminor...

An ad hoc, two-year analysis of the EffPac study found no signal of increased risk of long-term mortality, nor any adverse events, within two...
Luminor

Luminor DCB now reimbursed in France

Luminor 18 and Luminor 35 drug-coated balloons (DCB; iVascular) are now listed on the French LPPR list for de novo lesions of the femoropopliteal...
Interventional News for specialists

TINTIN trial shows “impressive” results at six months

The six-month results of TINTIN (Treatment with the lumINor DCB and The IVolutioN self-expanding stent) trial have been revealed at the annual meeting of the Cardiovascular and...

Novel paclitaxel-nano-coated balloon achieves lower incidence of restenosis than plain balloon...

  Two-year results of EffPac—a randomised controlled trial to assess the safety and efficacy of a novel drug-coated balloon (DCB) with a nanotechnology coating—have been...

Enrolment complete in T.I.N.T.I.N. study

iVascular has announced the completion of enrolment of patients in its T.I.N.T.I.N. (Treatment with the Luminor DCB and the iVolution self-expanding stent) study. The effectiveness...